FY2025 Earnings Estimate for LXEO Issued By Chardan Capital

Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Free Report) - Equities research analysts at Chardan Capital lowered their FY2025 earnings per share (EPS) estimates for shares of Lexeo Therapeutics in a research note issued to investors on Tuesday, March 25th. Chardan Capital analyst G. Livshits now anticipates that the company will post earnings per share of ($3.10) for the year, down from their prior forecast of ($2.30). Chardan Capital has a "Buy" rating and a $25.00 price objective on the stock. The consensus estimate for Lexeo Therapeutics' current full-year earnings is ($3.14) per share.

Lexeo Therapeutics (NASDAQ:LXEO - Get Free Report) last announced its quarterly earnings results on Monday, March 24th. The company reported ($0.78) EPS for the quarter, topping the consensus estimate of ($0.87) by $0.09.

Several other equities analysts have also recently issued reports on LXEO. Leerink Partners dropped their price target on Lexeo Therapeutics from $19.00 to $18.00 and set an "outperform" rating on the stock in a research report on Monday, March 24th. HC Wainwright reiterated a "buy" rating and set a $23.00 target price on shares of Lexeo Therapeutics in a research report on Wednesday, March 26th. Finally, Royal Bank of Canada dropped their price target on Lexeo Therapeutics from $24.00 to $20.00 and set an "outperform" rating for the company in a research report on Tuesday, March 25th. Five investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Buy" and a consensus price target of $22.80.

Remove Ads

Lexeo Therapeutics Stock Performance

Shares of LXEO stock traded down $0.43 during trading hours on Friday, hitting $3.04. The stock had a trading volume of 281,237 shares, compared to its average volume of 346,065. Lexeo Therapeutics has a twelve month low of $2.32 and a twelve month high of $19.50. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.95 and a quick ratio of 5.95. The firm has a market capitalization of $100.95 million, a PE ratio of -0.96 and a beta of 3.85. The stock's 50 day moving average is $4.02 and its 200 day moving average is $6.49.

Institutional Investors Weigh In On Lexeo Therapeutics

Several hedge funds have recently modified their holdings of the stock. Allostery Investments LP acquired a new position in shares of Lexeo Therapeutics during the fourth quarter worth $33,000. China Universal Asset Management Co. Ltd. acquired a new position in Lexeo Therapeutics in the 4th quarter worth $46,000. BNP Paribas Financial Markets boosted its position in Lexeo Therapeutics by 184.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 5,541 shares of the company's stock valued at $50,000 after buying an additional 3,591 shares during the last quarter. Price T Rowe Associates Inc. MD acquired a new position in shares of Lexeo Therapeutics in the fourth quarter worth about $69,000. Finally, SG Americas Securities LLC purchased a new position in Lexeo Therapeutics in the fourth quarter valued at about $72,000. 60.67% of the stock is currently owned by hedge funds and other institutional investors.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.